Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  icotinib hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 28 for your search:
Start Over
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV08, NCT01665417
Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IV-49, NCT01926171
High Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With EGFR 21 Exon Positive
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: AKTN-NSCLC-01, NCT02404675
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV62, NCT02103257
Icotinib Treat the Patient With Brain Metastasis Epidermal Growth Factor Receptor(EGFR) Mutant Non Small Cell Lung Cancer Comparing With Whole Brain Radiotherapy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: c-tong1201, NCT01724801
Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: GASTO1002, wsy003, NCT01996098
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV-59, NCT02125240
Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: YHH-201201, NCT01534585
Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ZhejiangCH-LCBM-1202, NCT01688713
Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IV-43, NCT01690390
Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV44, NCT01707329
Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: BD-IC-IV26, NCT01744925
Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Other
Protocol IDs: DEI-ADNSCLC, NCT01963195
Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ZYTOP 1401, NCT02009605
Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ICO-29, NCT01973725
Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV50, NCT01929200
Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: CH-GI-036, NCT01855854
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV06, NCT01843647
Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV51, NCT02062515
Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: Icotinib, NCT02191059
Icotinib for Completed Resected IB NSCLC With EGFR Mutation
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: GASTO1003, wsy004, NCT02264210
Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NFEC-2014-069, NCT02272127
Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SYSUCC-006, NCT02362230
Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ZYTOP1501, NCT02375022
Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 70 to less than 85
Sponsor: Other
Protocol IDs: HZFH CA15-01, NCT02375581
Start Over